Search research articles
Contact Us
Filters
Showing results (41-50 of 90) with videos related to
Page
of 9
Sort By:
Journal of the American Heart Association
|
March 9, 2023
Arrhythmogenic Cardiotoxicity Associated With Contemporary Treatments of Lymphoproliferative Disorders
Saadia Sherazi, Susan Schleede, Scott McNitt, et al.
Journal of the National Cancer Institute
|
January 2, 2017
T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment
Carla Casulo, Owen O'Connor, Andrei Shustov, et al.
Hematological Oncology
|
July 24, 2023
Personalised therapy in follicular lymphoma - is the dial turning?
Kim M Linton, Lena Specht, Astrid Pavlovsky, et al.
Leukemia & Lymphoma
|
August 16, 2022
Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: a phase II risk-adapted design
Anita Kumar, Carla Casulo, Erel Joffe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 2015
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
Carla Casulo, Michelle Byrtek, Keith L Dawson, et al.
Leukemia & Lymphoma
|
June 14, 2021
Body mass index and survival of patients with lymphoma
Dai Chihara, Melissa C Larson, Dennis P Robinson, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 22, 2016
Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era
Bradley D Hunter, Megan Herr, Philip J Meacham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2026
Duvelisib Induces Deep Responses in PTCL: Final Results of the Phase 2 PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma
Neha Mehta-Shah, Pier Luigi Zinzani, Eric D Jacobsen, et al.
Oncotarget
|
July 6, 2015
Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline
Mary Pulvino, Luojing Chen, David Oleksyn, et al.
Blood
|
October 6, 2021
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials
Carla Casulo, Jesse G Dixon, Jennifer Le-Rademacher, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 90) with videos related to
Sort By:
Page
of 9
Journal of the American Heart Association
|
March 9, 2023
Arrhythmogenic Cardiotoxicity Associated With Contemporary Treatments of Lymphoproliferative Disorders
Saadia Sherazi, Susan Schleede, Scott McNitt, et al.
Journal of the National Cancer Institute
|
January 2, 2017
T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment
Carla Casulo, Owen O'Connor, Andrei Shustov, et al.
Hematological Oncology
|
July 24, 2023
Personalised therapy in follicular lymphoma - is the dial turning?
Kim M Linton, Lena Specht, Astrid Pavlovsky, et al.
Leukemia & Lymphoma
|
August 16, 2022
Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: a phase II risk-adapted design
Anita Kumar, Carla Casulo, Erel Joffe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 2015
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
Carla Casulo, Michelle Byrtek, Keith L Dawson, et al.
Leukemia & Lymphoma
|
June 14, 2021
Body mass index and survival of patients with lymphoma
Dai Chihara, Melissa C Larson, Dennis P Robinson, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 22, 2016
Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era
Bradley D Hunter, Megan Herr, Philip J Meacham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2026
Duvelisib Induces Deep Responses in PTCL: Final Results of the Phase 2 PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma
Neha Mehta-Shah, Pier Luigi Zinzani, Eric D Jacobsen, et al.
Oncotarget
|
July 6, 2015
Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline
Mary Pulvino, Luojing Chen, David Oleksyn, et al.
Blood
|
October 6, 2021
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials
Carla Casulo, Jesse G Dixon, Jennifer Le-Rademacher, et al.
Page
of 9